Connection
Michael DiStefano to Cost-Benefit Analysis
This is a "connection" page, showing publications Michael DiStefano has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.842 |
|
|
|
-
DiStefano MJ, Kang SY, Yehia F, Morales C, Anderson GF. Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs. Value Health. 2021 03; 24(3):397-403.
Score: 0.608
-
DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
Score: 0.188
-
Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 Mar; 42(3):319-328.
Score: 0.046